Free Trial
NASDAQ:AVR

Anteris Technologies Global Q2 2025 TU Earnings Results & Report

Anteris Technologies Global logo
$6.30 -0.15 (-2.31%)
As of 11:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Anteris Technologies Global missed analyst earnings expectations but beat on revenue in its Q2 2025 TU results, released August 11, 2025. The company reported EPS of -$0.58 versus the -$0.5333 consensus estimate, while revenue of $0.62 million topped the $0.58 million estimate by $0.04 million.

Earnings Announcement Details

Quarter
Q2 2025 TU
Report Date
Time
Before Market Opens
Conference Call
6:00 PM ET

Anteris Technologies Global EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.5333
Beat/Miss
Missed by -$0.0467
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Anteris Technologies Global Revenue Results

Actual Revenue
$0.62 million
Expected Revenue
$0.58 million
Beat/Miss
Beat by +$38.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Anteris Technologies Global's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Anteris Technologies Global Q2 2025 TU Earnings FAQ

Anteris Technologies Global (NASDAQ:AVR) reported earnings of -$0.58 per share for Q2 2025 TU, missing the consensus estimate of -$0.5333. The report was announced on Monday, August 11, 2025.

Anteris Technologies Global reported revenue of $0.62 million for Q2 2025 TU, against a consensus estimate of $0.58 million.

Anteris Technologies Global's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Anteris Technologies Global on the company's earnings history page.

Anteris Technologies Global Earnings Headlines

Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.tc pixel
Anteris (NASDAQ: AVR) investor L1 Capital adds shares to its stake
See More Anteris Technologies Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anteris Technologies Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anteris Technologies Global and other key companies, straight to your email.

About Anteris Technologies Global

Anteris Technologies Global (NASDAQ:AVR) is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States. Anteris Technologies Global is led by Chief Executive Officer Wayne Patmore and trades on the Nasdaq under the symbol AVR.

View Anteris Technologies Global Profile